BIOVENTIX PLC – Interim Results
RNS Number : 5106Y BioVentix PLC 30 March 2026 Bioventix plc (“Bioventix” or the “Company”) Unaudited Interim Results
RNS Number : 5106Y BioVentix PLC 30 March 2026 Bioventix plc (“Bioventix” or the “Company”) Unaudited Interim Results
Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces its unaudited interim results for the six-month period ended 31 December 2020.
Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces that Bruce Hiscock will join the Board as Chief Financial Officer with immediate effect.
Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces its audited results for the year ended 30 June 2019.
Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces its unaudited interim financial results for the six-month period ended 31 December 2018.